openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Warnings sections page 1 of 1 · 1 matching rows.
warnings
WARNINGS Molybdenum has been reported to promote the mobilization of tissue copper, and increase urinary excretion of copper both in humans and animals. Excessive amounts of Molybdenum can therefore produce copper deficiency. The metabolism of copper in patients receiving Molybdenum supplements in TPN solution should be frequently checked. Purine and sulfur metabolic profiles should be frequently carried out in patients receiving molybdenum supplements in TPN solutions. Ammonium Molybdate Injection, USP is a hypotonic solution and should be administered in admixtures only. This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
ADVERSE REACTIONS The amount of molybdenum in Ammonium Molybdate Injection, USP is small and toxicity symptoms are unlikely to occur at the recommended dosage level.